What is mucosal melanoma?
Mucosal melanoma is a rare type of melanoma that starts in the pigment cells (melanocytes) of the mucous membranes. These are the moist linings inside the body, such as the inside of the nose and sinuses, the mouth, the anus and rectum, and the vulva and vagina.
It behaves very differently from melanoma of the skin. It is not caused by sun exposure, it grows in hidden places, and it is often found only when it is already large or has spread. It also has different genetic changes and responds less well to some treatments.
Because it is rare, most people are best treated in a specialist centre where surgeons, radiation oncologists and medical oncologists have experience with this disease.
1. How common is it?
Mucosal melanoma makes up only about 1% of all melanomas in people of European descent. In the United States it is diagnosed in roughly 2 people per million each year. It accounts for a much larger share of melanomas in people of Asian and African descent, because skin melanoma is less common in these groups.
| Feature | Details |
|---|---|
| Typical age | Usually over 60; median around 70 |
| Sex | More common in women overall, mainly because of vulvar and vaginal melanoma |
| Head and neck | About half of cases, mostly in the nose and sinuses, followed by the mouth |
| Anus and rectum | About a quarter of cases |
| Vulva and vagina | About a fifth of cases |
| Other sites | Rare: urinary tract, oesophagus, gallbladder, cervix |
Melanoma of the conjunctiva (the lining of the eye) is sometimes grouped with mucosal melanomas, but it behaves more like skin melanoma and is usually discussed separately.
2. Causes and risk factors
The cause of mucosal melanoma is largely unknown. Clear risk factors have not been established.
- Age is the strongest known factor; most people are over 60.
- Sunlight is not a cause, because these areas are not exposed to ultraviolet light.
- Pigmented patches (melanosis) in the mouth sometimes come before oral melanoma.
- Possible links with smoking, chronic irritation and some viruses have been suggested, but none is proven.
- Most cases are not inherited.
Genetic changes in the tumour
The tumours carry different genetic changes from skin melanoma, with far fewer of the typical ultraviolet-related mutations. Testing the tumour for these changes can open up targeted treatment.
| Gene | How often | Why it matters |
|---|---|---|
| KIT | About 15-20% have a mutation; more have extra copies | Some tumours with a KIT mutation respond to imatinib |
| NRAS | About 15-20% | No approved targeted drug yet |
| BRAF | About 5-10% | Can be treated with BRAF and MEK inhibitor tablets |
| SF3B1 | Common in anorectal and vulvovaginal tumours | Being studied as a marker |
| NF1 | Some tumours | Being studied |
Mucosal melanomas have a low tumour mutational burden, meaning fewer genetic changes overall. This is one reason why they respond less often to immunotherapy than skin melanoma.
3. How does it look?
Mucosal melanoma often looks less typical than skin melanoma. The ABCDE rules for moles do not apply well. In addition, many tumours sit in places that cannot be seen without special instruments.
3.1 General appearance
- Colour: often brown, black, grey or blue-black, sometimes with several shades. A significant number contain little or no pigment (amelanotic melanoma) and look pink, red or skin-coloured. These are easily mistaken for other conditions.
- Shape: a flat patch, a raised plaque, a lump or a polyp. Larger tumours often break down into an ulcer that bleeds easily.
- Spread along the surface: the flat, pigmented part around the tumour may extend well beyond what is visible, and several separate spots can appear. This makes complete surgical removal difficult.
3.2 Appearance by site
| Site | Typical appearance | Often mistaken for |
|---|---|---|
| Nose and sinuses | A fleshy, often dark or reddish polyp that bleeds easily, usually on one side | Nasal polyps, chronic sinusitis |
| Mouth | A dark patch or lump, most often on the hard palate or upper gum | Bruise, amalgam tattoo, harmless pigmentation |
| Anus and rectum | A dark or pink lump or polyp just inside the anus | Haemorrhoids (piles), polyps |
| Vulva | A dark, irregular patch or lump, often on the clitoris or labia | Benign pigmented spot, wart |
| Vagina | A dark or pale lump inside the vagina, often in the lower part | Polyp or other tumour |
3.3 Under the microscope
The tumour cells may be large and round (epithelioid), spindle-shaped or a mixture. Because some tumours have no pigment, pathologists use special stains to confirm the diagnosis.
SOX10, S100, Melan-A and HMB-45 are typical markers of melanoma. The tumour is also tested for genetic changes such as KIT, BRAF and NRAS.
4. Symptoms
Early mucosal melanoma often causes few or no symptoms. When symptoms appear, they depend on the site and are easily put down to more common, harmless problems. This is one of the main reasons for late diagnosis.
4.1 Symptoms by site
| Site | Common symptoms |
|---|---|
| Nose and sinuses | Blocked nose on one side, nosebleeds, discharge, reduced sense of smell, facial pain or swelling |
| Mouth | A dark spot or lump, bleeding, a sore that does not heal, loose teeth, dentures that no longer fit |
| Anus and rectum | Bleeding from the bottom, a lump, pain, a change in bowel habits, feeling that the bowel has not emptied |
| Vulva and vagina | Bleeding not related to periods or after menopause, discharge, itching, a lump, pain during sex |
| Urinary tract | Blood in the urine, difficulty passing urine |
4.2 Symptoms of advanced disease
- Swollen lymph nodes in the neck or groin
- Tiredness, weight loss and loss of appetite
- Cough or breathlessness if the lungs are affected
- Pain under the right ribs if the liver is affected
- Headaches or other neurological symptoms if the brain is affected
When to see a doctor
See a doctor if you have any of the following:
- Repeated nosebleeds or a blocked nose on one side that does not clear
- A dark patch or lump in the mouth, or a mouth sore that has not healed within three weeks
- Bleeding from the bottom that continues, especially if a lump is felt
- Unexpected vaginal bleeding, or any new dark patch or lump on the vulva
Most of these symptoms have harmless causes. They still need checking, especially if they persist.
5. Diagnosis
5.1 Examination and biopsy
The doctor examines the area, often with an endoscope: a thin camera passed into the nose, or a proctoscope for the anus. A biopsy of the lesion is needed for the diagnosis. Because many mucosal melanomas lack pigment, the diagnosis is sometimes a surprise for both patient and doctor.
5.2 Molecular testing
The tumour tissue should be tested for BRAF, KIT and NRAS mutations. The results help decide which drug treatment is possible if the melanoma comes back or spreads.
5.3 Imaging
| Test | Purpose |
|---|---|
| MRI | Shows the local extent of tumours in the head and neck or pelvis |
| CT | Shows bone involvement in the sinuses and checks the chest and abdomen |
| PET-CT | Looks for spread to lymph nodes and other organs |
| MRI of the brain | Checks for brain spread in advanced disease |
6. Staging
There is no single staging system for all mucosal melanomas.
Head and neck mucosal melanoma has its own AJCC (8th edition) system. Because it is so aggressive, even a tumour limited to the lining starts at T3, and the lowest stage is stage III.
| Stage | Main features (head and neck) |
|---|---|
| III | Tumour limited to the mucosa and the tissue just below it (T3), with no lymph node spread |
| IVA | Tumour growing into deep soft tissue, cartilage, bone or overlying skin (T4a), or spread to lymph nodes |
| IVB | Very advanced local tumour (T4b), involving the brain, skull base, lower cranial nerves or major arteries |
| IVC | Distant spread |
Vulvar melanoma is usually staged like skin melanoma, using tumour thickness (Breslow depth). For anorectal and vaginal melanoma, doctors usually use a simple three-step system:
- Stage I: localised disease
- Stage II: spread to regional lymph nodes
- Stage III: distant spread
7. Treatment
Treatment is planned by a multidisciplinary team. The main aims are to remove the tumour completely, control it locally and treat any spread.
7.1 Overview of treatments
| Treatment | When it is used | Key points |
|---|---|---|
| Surgery | Main treatment for disease that can be removed | Aims for clear margins; sinus surgery is often done endoscopically |
| Radiotherapy | After surgery in the head and neck, or when surgery is not possible | Improves local control; has not been shown to improve survival |
| Immunotherapy | Advanced disease; sometimes after surgery | PD-1 inhibitors, alone or with ipilimumab |
| Targeted therapy | Tumours with a BRAF or KIT mutation | Tablets; responses can be shorter-lived |
| Chemotherapy | When other options are unsuitable | Limited benefit |
7.2 Surgery
The surgeon tries to remove the tumour with a margin of healthy tissue. In the nose and sinuses, this is now often done endoscopically through the nostrils. Larger operations are needed for tumours that involve bone or the eye socket.
For anorectal melanoma, a local excision that preserves the anus is usually preferred when clear margins can be achieved. Studies have found no survival advantage for removing the rectum and anus (abdominoperineal resection), which requires a permanent stoma. The larger operation is reserved for tumours that cannot be removed in any other way.
For vulvar and vaginal melanoma, surgery ranges from wide local excision to more extensive operations. Sentinel lymph node biopsy may be used for vulvar melanoma.
7.3 Radiotherapy
In the head and neck, radiotherapy after surgery reduces the risk of the tumour coming back in the same place. It is commonly recommended, although it does not clearly improve survival. Radiotherapy is also used when surgery is not possible and to relieve symptoms such as bleeding or pain.
7.4 Immunotherapy
Checkpoint inhibitors help the immune system attack the melanoma. They are the standard drug treatment for advanced disease, but they work less often than in skin melanoma.
| Treatment | Response in mucosal melanoma | Notes |
|---|---|---|
| Nivolumab or pembrolizumab (anti-PD-1) | About 1 in 4 to 1 in 5 tumours shrink | Usually well tolerated |
| Nivolumab plus ipilimumab | About 1 in 3 tumours shrink in pooled data | More immune side effects |
| Ipilimumab alone | Fewer than 1 in 10 | Rarely used alone today |
In a pooled analysis of trials, about 23% of mucosal melanomas responded to nivolumab and about 37% to nivolumab plus ipilimumab. In skin melanoma the figures were about 41% and 60%.
After surgery, anti-PD-1 drugs are often offered to people at high risk of recurrence, based on trials in skin melanoma. Those trials included few people with mucosal melanoma, so the benefit in this group is less certain. A Chinese trial found that adjuvant toripalimab, another PD-1 inhibitor, gave similar results to high-dose interferon.
7.5 Targeted therapy
- KIT inhibitors: imatinib can shrink tumours with certain KIT mutations, especially in exon 11 or 13. In trials, about 16-29% of selected patients responded, but responses often lasted only months. Tumours with extra copies of KIT but no mutation rarely respond.
- BRAF and MEK inhibitors: for the small number of tumours with a BRAF V600 mutation, combinations such as dabrafenib with trametinib can be used, as in skin melanoma.
7.6 Clinical trials
Because results remain modest, joining a clinical trial is often a good option. Trials are testing new immunotherapy combinations, cell therapies and targeted drugs.
8. Prognosis
Mucosal melanoma has a poorer outlook than skin melanoma. It is often found late, and it tends to come back locally and spread through the bloodstream.
- Overall, about 25-35% of people are alive five years after diagnosis, with wide differences between studies.
- Outlook is better when the tumour is small, can be removed completely and has not spread to lymph nodes.
- Melanoma of the head and neck and of the vulva tends to have a somewhat better outlook than anorectal and vaginal melanoma.
- Local recurrence is common, even after apparently complete surgery. The disease often spreads to the lungs, liver, bones and brain.
Newer immunotherapy and targeted drugs have improved the outlook for some people with advanced disease. Long-term control is now possible for a minority, which was rare in the past.
9. Follow-up and living with mucosal melanoma
9.1 Follow-up
Because recurrence is common, follow-up is close. It usually includes examinations of the original site, often with an endoscope, every 3 months for the first two years and then less often. CT, MRI or PET-CT scans are typically done every 3-6 months at first.
9.2 Everyday life
- Surgery in the nose, mouth or pelvis can affect breathing through the nose, sense of smell, eating, speech, bowel function or sexual function. Rehabilitation, dental prosthetics and specialist nurses can help.
- Report new symptoms early, especially bleeding, a new lump, persistent headaches or pain.
- Immunotherapy side effects can appear months after starting treatment. Contact your team promptly about diarrhoea, breathlessness, rash or severe tiredness.
- Because the condition is rare and can affect intimate areas, many people find it hard to talk about. Patient organisations for mucosal melanoma offer information and peer support.
Resources
- Chang, A.E., Karnell, L.H. and Menck, H.R. (1998) ‘The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade’, Cancer, 83(8), pp. 1664-1678.
- Postow, M.A., Hamid, O. and Carvajal, R.D. (2012) ‘Mucosal melanoma: pathogenesis, clinical behavior, and management’, Current Oncology Reports, 14(5), pp. 441-448.
- Curtin, J.A. et al. (2006) ‘Somatic activation of KIT in distinct subtypes of melanoma’, Journal of Clinical Oncology, 24(26), pp. 4340-4346.
- Hayward, N.K. et al. (2017) ‘Whole-genome landscapes of major melanoma subtypes’, Nature, 545(7653), pp. 175-180.
- Carvajal, R.D. et al. (2011) ‘KIT as a therapeutic target in metastatic melanoma’, JAMA, 305(22), pp. 2327-2334.
- D’Angelo, S.P. et al. (2017) ‘Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis’, Journal of Clinical Oncology, 35(2), pp. 226-235.
- Lian, B. et al. (2022) ‘Toripalimab versus high-dose interferon-alpha2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial’, Annals of Oncology, 33(10), pp. 1061-1070.
- National Cancer Institute (2026) Melanoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq (Accessed: October 2026).
- Melanoma Research Foundation (2026) Mucosal Melanoma. Available at: https://melanoma.org/mucosal-melanoma/ (Accessed: October 2026).
- Cleveland Clinic (2026) Mucosal Melanoma. Available at: https://my.clevelandclinic.org/health/diseases/24643-mucosal-melanoma (Accessed: October 2026).
Prepared by the editorial team, October 2026.